Cordis Corporation Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Cordis Corporation's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Contents

• 1 List of Tables
  • 1.2 List of Figures
• 2 Company Snapshot
  • 2.1 Key Information
  • 2.2 Company Overview
  • 2.3 Financial Performance
  • 2.4 Industry Outlook - Cardiovascular Devices
• 3 Business Description
  • 3.1 Business Overview
  • 3.2 Major Products and Services
    • 3.2.1 Overview
• 4 History
• 5 Competitors
• 6 Key Employees
• 7 Key Employee Biographies
• 8 Company Statement
• 9 Locations And Subsidiaries
  • 9.1 Head Office
  • 9.2 Other Locations & Subsidiaries
• 10 Recent Developments
  • 10.1 Corporate Communications
    • 10.1.1 Jul 10, 2007: Cordis Appoints VP, Microelectronic Technologies
  • 10.2 Product News
    • 10.2.1 Jul 14, 2008: Gamida Cell Signs Collaboration Agreement With Biologics Delivery Systems Group
    • 10.2.2 May 05, 2008: Cordis Corporation Launches New Peripheral Angioplasty Balloon Catheter
    • 10.2.3 May 05, 2008: Cordis Corporation Launches New Peripheral Angioplasty Balloon Catheter
    • 10.2.4 Apr 09, 2008: NEJM Study Demonstrates Carotid Stenting With Embolic Protection Is Comparable To Surgery
    • 10.2.5 Apr 09, 2008: NEJM Study Demonstrates Carotid Stenting With Embolic Protection Is Comparable To Surgery
    • 10.2.6 Apr 01, 2008: Disappointing Resuts For Pimecrolimus, Investigational Anti-restenosis Drug
    • 10.2.7 Mar 30, 2008: Three Year Follow-Up Data Suggest Better Outcomes Were Maintained With The CYPHER Sirolimus-Eluting Coronary Stent Compared To Brachytherapy In Patients With In-Stent Reblockage
    • 10.2.8 Mar 17, 2008: Cordis Corporation Receives US Food and Drug Administration Clearance For S.M.A.R.T. Nitinol Stent Transhepatic Biliary System For 120mm and 150 mm Lengths
    • 10.2.9 Feb 21, 2008: Cordis Launches Steerable Guidewires
    • 10.2.10 Feb 08, 2008: Balloon Catheters Recalled
    • 10.2.11 Feb 08, 2008: FDA Recalls Cordis Balloon Catheters With Potentially Fatal Defects
    • 10.2.12 Nov 05, 2007: Pooled Analysis Of Long-term Data Suggests Cypher Sirolimus Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
    • 10.2.13 Oct 22, 2007: New Long-Term Data Suggest Clinical Differences In Safety And Efficacy Between Cypher Sirolimus-Eluting Coronary Stent And Taxus Stent
    • 10.2.14 Oct 20, 2007: ECLIPSE Trial
    • 10.2.15 Oct 17, 2007: Cordis Corporation Announces Clinical Studies And Events At Tct 2007
    • 10.2.16 Sep 25, 2007: Cordis Corporation Introduces Fire Star Rx Ptca Dilatation Catheter
    • 10.2.17 Sep 25, 2007: Cordis Corporation Introduces Dura Star Rx PTCA Dilatation Catheter
    • 10.2.18 Sep 21, 2007: The CypherSirolimus-Eluting Coronary Stent Outperforms The Taxus Stent In Small Coronary Vessels
    • 10.2.19 Sep 13, 2007: Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates
    • 10.2.20 Sep 04, 2007: Two-Year Outcomes From Large Head-To-Head Clinical Trial Indicate Similar Safety Profile In Diabetic Patients For Cypher Sirolimus-Eluting Coronary Stent And Taxus Stent
    • 10.2.21 Aug 31, 2007: Enrollment Completed in Trial for Vascular Closure Device
    • 10.2.22 Jun 04, 2007: New Study Suggests Better Patient Outcomes With Cypher Sirolimus-Eluting Coronary Stent
    • 10.2.23 May 22, 2007: Cypher Sirolimus-Eluting Coronary Stent Had Similar Results To Bypass Surgery
    • 10.2.24 Mar 30, 2007: Cordis Corporation Starts Pivotal Trial for ExoSeal Vascular Closure Device
    • 10.2.25 Mar 26, 2007: Two-Year Patient Registry Results Support Safety And Efficacy Of Cypher Sirolimus-Eluting Coronary Stent In Real World'' Uses
    • 10.2.26 Mar 20, 2007: Cordis Corporation To Emphasize Commitment To Interventional Cardiology At ACC.07
    • 10.2.27 Dec 07, 2006: Cordis Corporation Announces Clinical And Educational Programs For The CypherSirolimus-Eluting Coronary Stent
    • 10.2.28 Nov 15, 2006: Preliminary Long-Term Clinical Data Show Promising Results For The CYPHER Sirolimus-eluting Coronary Stent In Patients With Multi-Vessel Disease
    • 10.2.29 Oct 24, 2006: Cordis To Study Impact Of Contributing Factors To Stent Thrombosis In Expansion Of 30,000-Stent Patient Registry
    • 10.2.30 Oct 23, 2006: New Randomized Clinical Trial Results Show The Cypher Sirolimus-Eluting Coronary Stent Outperformed The Taxus Stent In Long Coronary Lesions
    • 10.2.31 Oct 19, 2006: New Independent Analysis Of Long-Term Safety Data For The Cypher Sirolimus-Eluting Coronary Stent To Be Presented At Tct 2006
    • 10.2.32 Oct 04, 2006: Data Suggest Different Outcomes Between The Cypher Sirolimus-Eluting Coronary Stent And The Taxus Stent In Real World'' Settings And Small Vessels
    • 10.2.33 Sep 26, 2006: Cordis Corporation Launches Cypher Select Plus Stent
    • 10.2.34 Sep 26, 2006: US Food And Drug Administration Approves ANGIOGUARD Emboli Capture Guidewire
    • 10.2.35 Sep 26, 2006: US Food And Drug Administration Approves PRECISE Nitinol Stent
    • 10.2.36 Sep 13, 2006: Study In New England Journal Of Medicine Suggests Heart Attack Patients Fare Better With Cypher Sirolimus eluting Coronary Stents Than Bare Metal Stents
    • 10.2.37 Sep 06, 2006: Data Suggest The Cypher Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
    • 10.2.38 Sep 06, 2006: Data Suggests CYPHER Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
    • 10.2.39 Aug 29, 2006: New Clinical Data for Cypher Sirolimus-Eluting Coronary Stent & Innovative Cordis Technologies to Be Showcased at World Congress of Cardiology 2006
    • 10.2.40 Aug 28, 2006: Cordis STEER-IT Deflecting Tip Guidewire Now Available In The United States, Europe And Canada
    • 10.2.41 Jun 28, 2006: Cordis Corporation And ClearStream Technologies Group, plc, Sign Distribution Agreement For New Balloon Dilation Catheter
    • 10.2.42 Jun 22, 2006: Cordis Corporation''s Third-Generation Coronary Stent Approved For Use In Europe
    • 10.2.43 May 18, 2006: Cordis Announces First Patient Treated With Dual-Drug Coronary Stent
    • 10.2.44 May 17, 2006: Cordis Corporation Submits Pre-Market Approval Supplement For Direct Stenting
    • 10.2.45 May 16, 2006: Study Suggests Drug-Eluting Stent Type And Vessel Size Are Important Predictors Of Reblockage In Coronary Artery
    • 10.2.46 May 15, 2006: Patient Registry To Evaluate Long-Term Safety And Efficacy Of Cordis Next Generation Drug-Eluting Coronary Stents In Clinical Practice
  • 10.3 Product Approvals
    • 10.3.1 Mar 17, 2008: Cordis Corporation Receives US Food and Drug Administration Clearance For S.M.A.R.T. Nitinol Stent Transhepatic Biliary System For 120mm and 150 mm Lengths
    • 10.3.2 Sep 26, 2006: US Food And Drug Administration Approves ANGIOGUARD Emboli Capture Guidewire
    • 10.3.3 Jun 22, 2006: Cordis Corporation''s Third-Generation Coronary Stent Approved For Use In Europe
  • 10.4 Clinical Trials
    • 10.4.1 Apr 09, 2008: NEJM Study Demonstrates Carotid Stenting With Embolic Protection Is Comparable To Surgery
    • 10.4.2 Apr 09, 2008: NEJM Study Demonstrates Carotid Stenting With Embolic Protection Is Comparable To Surgery
    • 10.4.3 Apr 01, 2008: Disappointing Resuts For Pimecrolimus, Investigational Anti-restenosis Drug
    • 10.4.4 Mar 30, 2008: Three Year Follow-Up Data Suggest Better Outcomes Were Maintained With The CYPHER Sirolimus-Eluting Coronary Stent Compared To Brachytherapy In Patients With In-Stent Reblockage
    • 10.4.5 Nov 05, 2007: Pooled Analysis Of Long-term Data Suggests Cypher Sirolimus Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
    • 10.4.6 Oct 22, 2007: New Long-Term Data Suggest Clinical Differences In Safety And Efficacy Between Cypher Sirolimus-Eluting Coronary Stent And Taxus Stent
    • 10.4.7 Oct 20, 2007: ECLIPSE Trial
    • 10.4.8 Sep 21, 2007: The CypherSirolimus-Eluting Coronary Stent Outperforms The Taxus Stent In Small Coronary Vessels
    • 10.4.9 Sep 13, 2007: Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates
    • 10.4.10 Sep 04, 2007: Two-Year Outcomes From Large Head-To-Head Clinical Trial Indicate Similar Safety Profile In Diabetic Patients For Cypher Sirolimus-Eluting Coronary Stent And Taxus Stent
    • 10.4.11 Aug 31, 2007: Enrollment Completed in Trial for Vascular Closure Device
    • 10.4.12 Jun 04, 2007: New Study Suggests Better Patient Outcomes With Cypher Sirolimus-Eluting Coronary Stent
    • 10.4.13 May 22, 2007: Cypher Sirolimus-Eluting Coronary Stent Had Similar Results To Bypass Surgery
    • 10.4.14 Mar 30, 2007: Cordis Corporation Starts Pivotal Trial for ExoSeal Vascular Closure Device
    • 10.4.15 Mar 26, 2007: Two-Year Patient Registry Results Support Safety And Efficacy Of Cypher Sirolimus-Eluting Coronary Stent In Real World'' Uses
    • 10.4.16 Mar 20, 2007: Cordis Corporation To Emphasize Commitment To Interventional Cardiology At ACC.07
    • 10.4.17 Dec 07, 2006: Cordis Corporation Announces Clinical And Educational Programs For The CypherSirolimus-Eluting Coronary Stent
    • 10.4.18 Nov 15, 2006: Preliminary Long-Term Clinical Data Show Promising Results For The CYPHER Sirolimus-eluting Coronary Stent In Patients With Multi-Vessel Disease
    • 10.4.19 Oct 24, 2006: Cordis To Study Impact Of Contributing Factors To Stent Thrombosis In Expansion Of 30,000-Stent Patient Registry
    • 10.4.20 Oct 23, 2006: New Randomized Clinical Trial Results Show The Cypher Sirolimus-Eluting Coronary Stent Outperformed The Taxus Stent In Long Coronary Lesions
    • 10.4.21 Oct 19, 2006: New Independent Analysis Of Long-Term Safety Data For The Cypher Sirolimus-Eluting Coronary Stent To Be Presented At Tct 2006
    • 10.4.22 Oct 04, 2006: Data Suggest Different Outcomes Between The Cypher Sirolimus-Eluting Coronary Stent And The Taxus Stent In Real World'' Settings And Small Vessels
    • 10.4.23 Sep 13, 2006: Study In New England Journal Of Medicine Suggests Heart Attack Patients Fare Better With Cypher Sirolimus eluting Coronary Stents Than Bare Metal Stents
    • 10.4.24 Sep 06, 2006: Data Suggest The Cypher Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
    • 10.4.25 May 18, 2006: Cordis Announces First Patient Treated With Dual-Drug Coronary Stent
    • 10.4.26 May 15, 2006: Patient Registry To Evaluate Long-Term Safety And Efficacy Of Cordis Next Generation Drug-Eluting Coronary Stents In Clinical Practice
  • 10.5 Other Significant Developments
    • 10.5.1 May 23, 2007: Cordis Signs Agreement With Medinol
• 11 Cordis Corporation Pipeline Products
  • 11.1 Cordis Corporation Product Pipeline Analysis
    • 11.1.1 Cordis Corporation Pipeline Products By Equipment Type
    • 11.1.2 Cordis Corporation Pipeline Products By Development Stage
    • 11.1.3 Cordis Corporation Pipeline Products By Therapy Area
    • 11.1.4 Cordis Corporation Pipeline Products By Clinical Trials
    • 11.1.5 Cordis Corporation Pipeline Products By News Summary
  • 11.2 ExoSeal Vascular Closure Device
    • 11.2.1 Product Description
    • 11.2.2 Product Status
    • 11.2.3 Clinical Trials
    • 11.2.4 Product Milestone
  • 11.3 SymBio Pimecrolimus/Paclitaxel-eluting Stent
    • 11.3.1 Product Description
    • 11.3.2 Product Status
    • 11.3.3 Clinical Trials
    • 11.3.4 Product Milestone
  • 11.4 Sirolimus-Eluting BX Velocity Balloon-Expandable Stent
    • 11.4.1 Product Description
    • 11.4.2 Product Status
    • 11.4.3 Clinical Trials
    • 11.4.4 Product Milestone
  • 11.5 Regatta HS guidewire
    • 11.5.1 Product Description
    • 11.5.2 Product Status
    • 11.5.3 Product Milestone
  • 11.6 Nevo
    • 11.6.1 Product Description
    • 11.6.2 Product Status
  • 11.7 Cypher Elite
    • 11.7.1 Product Description
    • 11.7.2 Product Status
    • 11.7.3 Clinical Trials
  • 11.8 Myostar Catheter
    • 11.8.1 Product Description
    • 11.8.2 Product Status
    • 11.8.3 Clinical Trials
    • 11.8.4 Product Milestone
    • 11.8.5 Product Patent Details
  • 11.9 Myostar Catheter
    • 11.9.1 Product Description
    • 11.9.2 Product Status
    • 11.9.3 Clinical Trials
    • 11.9.4 Product Milestone
    • 11.9.5 Product Patent Details
  • 11.10 NEVO Sirolimus-eluting Coronary Stent
    • 11.10.1 Product Description
    • 11.10.2 Product Status
    • 11.10.3 Product Patent Details
• 12 Appendix
  • 12.1 Methodology
    • 12.1.1 Coverage
    • 12.1.2 Secondary Research
    • 12.1.3 Primary Research
    • 12.1.4 Expert Panel Validation
  • 12.2 Contact Us
  • 12.3 About Global Markets Direct
  • 12.4 Disclaimer
• 1 List of Tables
  • Table 1: Cordis Corporation,Key Facts
  • Table 2: Cordis Corporation, Key Employees,
  • Table 3: Cordis Corporation, Other Locations
  • Table 4: Cordis Corporation Pipeline Products by Equipment Type
  • Table 5: Cordis Corporation Pipeline Products By Development Stage
  • Table 6: Cordis Corporation Pipeline Products By Therapy Area
  • Table 7: Cordis Corporation Pipeline Products By Clinical Trials
  • Table 8: Cordis Corporation Pipeline Products By News Summaries
  • 1.2 List of Figures
  • Figure 1: Cordis Corporation Pipeline Products By Development Stage
  • Figure 2: Cordis Corporation Pipeline Products By News Summary
  • Figure 3: Global Markets Direct Methodology